beta blockers and glp 1 GLP-1 receptor agonists next-generation metabolic hormone therapies in chronic kidney disease The Role of GLP-1RA Medications

GSSG was modeled as partially protonated with a net charge of 2 and was parameterized with the CHARMM General Force Field (CGenFF) 71 using the CHARMMGUI 72

Overall, the collective pleiotropic effects of GLP-1 (Fig

If a dose of a once-weekly GLP-1 medication is missed, patients should follow product-specific guidance

Vutiglabridin overcomes the weight-loss plateau of low-potency GLP-1RAs Vutiglabridin overcomes the weight-loss plateau of low-potency GLP-1RAs

Real-world risk of hypoglycemia-related hospitalization in Japanese patients with type 2 diabetes using SGLT2 inhibitors: a nationwide cohort study

Pedersen: Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice